Key result
DPP-4 inhibitors were associated with significantly lower all-cause mortality compared to non-DPP-4 inhibitors in hospitalized heart failure patients with diabetes mellitus (HR 0.370, P=0.003).
Why the study?
Do dipeptidyl peptidase-4 (DPP-4) inhibitors reduce mortality in hospitalized heart failure patients with diabetes mellitus?
Population
293 hospitalized heart failure patients with diabetes mellitus
Comparison
Dipeptidyl peptidase-4 (DPP-4) inhibitors vs Non-DPP-4 inhibitors (propensity score-matched)
Design
Cohort
Authors
Loading...
DPP-4 inhibitor use was associated with lower mortality but should not change practice; leaves open confirmation in randomized trials.
Observational (n=962)
Do dipeptidyl peptidase-4 (DPP-4) inhibitors reduce mortality in hospitalized heart failure patients with diabetes mellitus?
Effect estimate: HR 0.370
Absolute Event Rate: 14.5% vs 41%
p-value: p=0.003
In hospitalized heart failure patients with diabetes mellitus, the use of DPP-4 inhibitors was associated with significantly lower cardiac and all-cause mortality.
Sato et al. (2015) conducted an observational in Hospitalized heart failure with diabetes mellitus (n=962). Dipeptidyl peptidase-4 (DPP-4) inhibitors vs. Non-DPP-4 inhibitors was evaluated on All-cause mortality (HR 0.370, p=0.003). DPP-4 inhibitors were associated with significantly lower all-cause mortality compared to non-DPP-4 inhibitors in hospitalized heart failure patients with diabetes mellitus (HR 0.370, P=0.003).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: